Annual Drug Patent Expirations for SAXENDA
Saxenda is a drug marketed by Novo and is included in a single NDA. It’s accessible from two suppliers. There are twenty-three patents defending this drug.
SAXENDA drug worth tendencies.
Drug patent litigation for SAXENDA.
This drug has thirty-eight patent members of the family in 13 international locations.
The generic ingredient in SAXENDA is liraglutide recombinant. Two suppliers are listed for this compound. Further particulars can be found on the liraglutide recombinant profile web page.
For extra info on how DrugPatentWatch can assist along with your pharmaceutical enterprise intelligence wants, contact admin@DrugPatentWatch.com or go to www.DrugPatentWatch.com
Make Higher Choices with DrugPatentWatch
Copyright © DrugPatentWatch. Initially revealed at New patent for NOVO drug SAXENDA